Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Linde PLC (LIN) vs GeneDx Holdings Corp (WGS) Price & Performance

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Linde PLC vs GeneDx Holdings Corp — how do they compare? Linde PLC trades at $483.98 (market cap $222.05B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Linde PLC is far larger — about 109.9× GeneDx Holdings Corp's market cap, and Linde PLC pays a 1.33% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Linde PLC for 88 Days and GeneDx Holdings Corp for 19 Days on average.

LINWGS
Market Cap
$222.05B$2.02B
Volume
2,116,440734,640
Sector
Basic MaterialsHealth
52-Week High
$546.64$167.51
52-Week Low
$389.38$34.51
Typical Hold Time
88 Days19 Days
Enterprise Value
$245.17B$2.05B
Dividend Yield
1.33%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Linde PLC

LIN trades at $483.98, down 1.22% on the day, with a bullish technical signal from moving averages and strong support near $482. The company reported record Q2 2026 EPS of $4.50, beating estimates, and maintains robust profitability with a 20.43% net income margin. Revenue growth is steady, projected at $35.4B for 2026, while valuation multiples like the 31.08 P/E reflect premium pricing. Analyst sentiment is overwhelmingly positive, with 89.66% buy ratings and a $557.10 consensus price target, citing LIN's role in AI chip supply chains.

The outlook for LIN is favorable, driven by earnings beats, a record $8.1B project backlog, and strategic positioning in high-growth sectors like electronics. Key risks include elevated valuation requiring sustained growth, rising debt-to-asset ratios, and margin pressures from increased capital expenditure. Investors should weigh the company's strong execution against potential sector-wide competition and macroeconomic headwinds affecting industrial demand.

GeneDx Holdings Corp

GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.

The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LIN
0% Buy100% Sell
Avg holding period · 88 Days
WGS
100% Buy0% Sell
Avg holding period · 19 Days

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN →

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS →